Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

09-11-2020 | ACR 2020 | Conference coverage | Video

FAST trial suggests comparable CV safety of febuxostat vs allopurinol

Investigator Fernando Pérez-Ruiz talks about the results of the FAST trial, showing no increase in the risk for cardiovascular events with febuxostat versus allopurinol treatment in patients with gout (4:14).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

09-11-2020 | ACR 2020 | Conference coverage | News

FAST: No increase in cardiovascular risk with febuxostat vs allopurinol

12-03-2018 | Gout | News

CARES trial published: Increased cardiovascular death risk with febuxostat

22-02-2019 | Gout | News

FDA warns of increased death risk with febuxostat

03-12-2019 | Gout | News

Febuxostat and allopurinol may raise acute kidney injury risk
Image Credits